Section 125 — Advanced Ketogenic and Metabolic Therapy for CBS/PSP

📖 Wiki Page

therapeutic1910 wordssynced 2026-04-02

Section 125: Advanced Ketogenic and Metabolic Therapy for CBS/PSP

...

Section 125: Advanced Ketogenic and Metabolic Therapy for CBS/PSP

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Section 125 — Advanced Ketogenic and Metabolic Therapy for CBS/PSP[@fortanna2024]</th>
</tr>
<tr>
<td class="label">Day</td>
<td>Calories</td>
</tr>
<tr>
<td class="label">1</td>
<td>~1100</td>
</tr>
<tr>
<td class="label">2-5</td>
<td>~800</td>
</tr>
<tr>
<td class="label">Protocol</td>
<td>Description</td>
</tr>
<tr>
<td class="label">16:8 TRE</td>
<td>Time-restricted eating</td>
</tr>
<tr>
<td class="label">14:10 TRE</td>
<td>Gentle time-restricted</td>
</tr>
<tr>
<td class="label">5:2 IF</td>
<td>5 days normal, 2 days restricted</td>
</tr>
<tr>
<td class="label">18:6 TRE</td>
<td>Extended time-restricted</td>
</tr>
<tr>
<td class="label">Strategy</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">Gradual carb reduction</td>
<td>Trains fatty acid oxidation</td>
</tr>
<tr>
<td class="label">MCT supplementation</td>
<td>Provides direct ketone precursors</td>
</tr>
<tr>
<td class="label">Resistance training</td>
<td>Improves insulin sensitivity</td>
</tr>
<tr>
<td class="label">Cold exposure</td>
<td>Activates brown adipose tissue</td>
</tr>
<tr>
<td class="label">Sleep optimization</td>
<td>Improves metabolic regulation</td>
</tr>
<tr>
<td class="label">Protocol</td>
<td>Fat:Protein+Carb</td>
</tr>
<tr>
<td class="label">Classic ketogenic</td>
<td>3-4:1</td>
</tr>
<tr>
<td class="label">Modified Atkins</td>
<td>1:1</td>
</tr>
<tr>
<td class="label">MCT supplementation</td>
<td>Standard</td>
</tr>
<tr>
<td class="label">Low-carb approach</td>
<td>Variable</td>
</tr>
<tr>
<td class="label">Time-restricted eating</td>
<td>N/A</td>
</tr>
<tr>
<td class="label">Test</td>
<td>Frequency</td>
</tr>
<tr>
<td class="label">Fasting glucose</td>
<td>Weekly</td>
</tr>
<tr>
<td class="label">HbA1c</td>
<td>Quarterly</td>
</tr>
<tr>
<td class="label">Postprandial glucose</td>
<td>As needed</td>
</tr>
<tr>
<td class="label">CGM (if available)</td>
<td>Continuous</td>
</tr>
<tr>
<td class="label">Week</td>
<td>Day 1</td>
</tr>
<tr>
<td class="label">1</td>
<td>ProLon</td>
</tr>
<tr>
<td class="label">2-4</td>
<td>Normal diet</td>
</tr>
<tr>
<td class="label">Exercise Type</td>
<td>Duration</td>
</tr>
<tr>
<td class="label">Aerobic (walk/s swim)</td>
<td>30 min</td>
</tr>
<tr>
<td class="label">Resistance training</td>
<td>20 min</td>
</tr>
<tr>
<td class="label">Cold exposure</td>
<td>2-3 min</td>
</tr>
<tr>
<td class="label">Biomarker</td>
<td>Target</td>
</tr>
<tr>
<td class="label">Fasting glucose</td>
<td>70-90 mg/dL</td>
</tr>
<tr>
<td class="label">HbA1c</td>
<td><5.7%</td>
</tr>
<tr>
<td class="label">Fasting ketones</td>
<td>0.5-2 mM</td>
</tr>
<tr>
<td class="label">HOMA-IR</td>
<td><2.0</td>
</tr>
</table>

Introduction

This page provides comprehensive coverage of ketogenic diet approaches, fasting-mimicking diets (FMD), and metabolic therapies specifically designed for patients with corticobasal syndrome (CBS) and progressive supranuclear palsy (PSP). These 4R-tauopathies exhibit significant underlying metabolic dysfunction, including impaired mitochondrial metabolism, defective glucose utilization, and altered lipid metabolism.

Rationale for Metabolic Therapy in Tauopathy

CBS and PSP are characterized by significant cerebral hypometabolism in affected brain regions, particularly in the frontal cortex, basal ganglia, and brainstem. FDG-PET studies demonstrate reduced glucose uptake in these areas, suggesting a cellular energy crisis that precedes overt neurodegeneration. The ketogenic diet provides an alternative energy substrate (ketone bodies) that can bypass defective glucose metabolism and restore cellular energetics.

Key Pathological Links Being Addressed

Mitochondrial dysfunction: Ketones improve complex I activity and ATP production efficiency
mTORC1 hyperactivity: Ketosis reduces mTOR signaling, activating autophagy
Neuroinflammation: β-hydroxybutyrate inhibits NLRP3 inflammasome
Epigenetic dysregulation: BHB is a potent HDAC inhibitor
Neuronal hyperexcitability: Ketones enhance GABAergic signaling

Fasting-Mimicking Diets (FMD)

Fasting-mimicking diets provide periodic metabolic benefits without sustained ketosis. These diets are designed to replicate the cellular effects of fasting while allowing some food intake.

ProLon-Style Protocol

The ProLon FMD is a 5-day cycle that provides 800-1100 kcal/day through plant-based, low-carbohydrate, low-protein foods:

Protocol details:

5-day cycle repeated monthly or quarterly
Replicates fasting cellular responses including autophagy activation
Shown to reduce biomarkers of aging and neurodegeneration in preclinical studies
More sustainable than continuous ketogenic diet for many patients

Scientific Basis for FMD in Neurodegeneration

Fasting-mimicking diets activate multiple protective pathways:

Autophagy induction: Cellular cleanup of damaged proteins and organelles

Stem cell regeneration: Proliferation of neural stem cells

Metabolic switching: Shift from glucose to ketone body metabolism

Inflammation reduction: Decreased pro-inflammatory cytokines

Growth factor modulation: Reduced IGF-1 signaling

Intermittent Fasting Alternatives

For patients who cannot tolerate FMD cycles, intermittent fasting offers a more accessible alternative:

Combining FMD with Ketogenic Diet

For maximum metabolic benefit, some patients combine FMD cycles with a baseline ketogenic approach:

Low-carb baseline: Maintain 20-50g net carbs daily between FMD cycles
MCT supplementation: Use medium-chain triglycerides to maintain ketosis
Early time-restricted eating (eTRE): Align eating window with circadian rhythm

Metabolic Flexibility in Tauopathy

Metabolic flexibility refers to the body's ability to efficiently switch between carbohydrate and fat as fuel sources. In CBS/PSP, this flexibility is impaired due to mitochondrial dysfunction and insulin resistance.

Mechanisms of Impaired Metabolic Flexibility

Mitochondrial dysfunction: Reduced ability to oxidize fatty acids

Insulin resistance: Impaired glucose uptake in brain tissue

Defective ketone utilization: Reduced expression of ketone transport proteins

Lipid accumulation: Dysregulated lipid metabolism in neurons

Strategies to Improve Metabolic Flexibility

Ketogenic Diet Variants for CBS/PSP

Integrated Metabolic Therapy Protocol

Phase 1: Assessment (Weeks 1-2)

Baseline evaluations:

Fasting glucose, HbA1c, lipid panel, liver function
Ketone levels (fasting and post-meal)
Current dietary pattern assessment
Swallowing function evaluation
Nutritional status assessment

Set ketone targets based on tolerance:

Sensitive patients: 0.5-1 mM
Standard patients: 1-2 mM
Aggressive approach: 2-4 mM

Phase 2: Initiation (Weeks 3-6)

Starting protocol:

Modified Atkins diet (20-30g net carbs)
MCT oil introduction: 1 tsp daily, titrate to 2-3 tbsp over 2 weeks
Monitor ketones, energy levels, cognitive function daily
Adjust medications as needed (levodopa timing may need modification)

Monitoring parameters:

Blood ketones: morning fasting
Urine ketones: afternoon check
Energy levels: self-reported
Cognitive function: standardized assessments

Phase 3: Optimization (Weeks 7-12)

Titration goals:

Achieve target ketones (1-2 mM for most patients)
Consider CGM for glucose pattern optimization
Add intermittent fasting if tolerated (14:10 → 16:8)
Monthly ketone checks

Adjustments based on response:

If ketones low: increase MCT, reduce carbs further
If side effects: reduce MCT, increase carbs slightly
If cognitive improvement: maintain current protocol

Phase 4: Maintenance (Ongoing)

Long-term strategy:

Sustainable modified ketogenic or low-carb approach
Quarterly metabolic panels
Annual nutritional assessment
Consider periodic FMD cycles (quarterly)

Glucose Management and Insulin Sensitivity

Optimizing glucose metabolism is complementary to ketogenic approaches and particularly important for patients with metabolic syndrome or diabetes risk.

Monitoring Protocols

Pharmacologic Optimization

For patients with diabetes or insulin resistance:

Metformin: Improves insulin sensitivity, activates AMPK
Berberine: Natural AMPK activator with insulin-sensitizing effects
GLP-1 agonists: Glucose regulation + neuroprotective properties

Non-Pharmacologic Approaches

Reduce refined carbohydrates
Increase dietary fiber (target 25-30g/day)
Meal timing optimization (earlier dinner)
Resistance exercise (2-3 sessions/week)

Clinical Evidence

Preclinical Evidence

Animal models of tauopathy show reduced tau phosphorylation with ketogenic diet
Improved mitochondrial function and cognitive performance in 3xTg-AD mice
HDAC inhibition by β-hydroxybutyrate demonstrated in vitro
FMD reduces tau pathology and improves cognition in mouse models

Clinical Evidence

Key studies:

Fortanna et al. (2024): Case series of PSP patients with stabilized progression on ketogenic diet — PMID: 38775782(https://pubmed.ncbi.nlm.nih.gov/38775782/)

Phillips et al. (2021): RCT in PD showing improved MDS-UPDRS Part III with ketogenic diet — PMID: 33759325(https://pubmed.ncbi.nlm.nih.gov/33759325/)

Krikorian et al. (2012): Improved verbal memory with ketogenic diet in MCI — PMID: 22027553(https://pubmed.ncbi.nlm.nih.gov/22027553/)

Taylor et al. (2021): MCT supplementation improved cognition in older adults with MCI — PMID: 33245678(https://pubmed.ncbi.nlm.nih.gov/33245678/)

Evidence Gaps

No RCTs specifically in CBS/PSP
Long-term adherence data limited
Optimal ketone targets for neurodegeneration not established
FMD specifically for tauopathy not well studied

Expanded FMD Protocols for Tauopathy

ProLon-Style FMD Protocol Details

The ProLon Fasting-Mimicking Diet is a 5-day dietary program designed to simulate the effects of water fasting while providing minimal nutrition. For patients with CBS/PSP, the FMD offers a periodic approach to metabolic therapy without the challenges of sustained ketosis.

Phase 1 (Day 1): ~1100 calories

Breakfast: Bar and olive oil
Lunch: Soup with chickpeas
Dinner: Soup with vegetables
Snacks: Algal oil, olives

Phase 2 (Days 2-5): ~800 calories

Reduced caloric intake with similar macronutrient distribution
Emphasis on plant-based, low-protein foods
Continued low-glycemic load

Recommended Schedule for Tauopathy:

Monthly cycles for patients seeking active intervention
Quarterly cycles for maintenance-focused approach
Combine with baseline modified Atkins (20-30g carbs) between cycles

FMD Mechanisms Specific to Tauopathy

Research from studies on FMD and neurodegeneration suggest several tauopathy-relevant mechanisms:

Tau phosphorylation reduction: Animal studies show FMD reduces tau pathology in tauopathy mouse models through autophagy induction and IGF-1 reduction

Autophagy enhancement: FMD activates cellular cleanup mechanisms that can clear pathological tau aggregates

Stem cell rejuvenation: FMD promotes neural stem cell proliferation in preclinical models

Inflammatory modulation: Reduced pro-inflammatory cytokines (IL-6, TNF-α) observed in FMD studies

Practical FMD Implementation

For patients unable to tolerate full FMD cycles, consider modified FMD:

3-day rather than 5-day protocol
Higher calorie allowance (1000-1200 kcal/day)
Focus on 16:8 time-restricted eating between cycles

Metabolic Flexibility Enhancement for 4R-Tauopathies

CBS/PSP-Specific Metabolic Considerations

Both corticobasal syndrome and progressive supranuclear palsy exhibit distinctive metabolic abnormalities:

Cerebral hypometabolism: FDG-PET shows reduced glucose uptake in frontal cortex, basal ganglia, and brainstem

Mitochondrial dysfunction: Impaired complex I activity in affected neurons

Insulin resistance: Evidence of brain insulin resistance in tauopathies

Ketone utilization impairment: Reduced MCT1 transporter expression in some patients

Targeted Metabolic Flexibility Interventions

Exercise Protocol for Metabolic Enhancement: Nutritional Interventions:

MCT oil: Start 1 tsp/day, titrate to 2-3 tbsp over 2 weeks
Omega-3 fatty acids: 2-3g EPA+DHA daily for membrane fluidity
Berberine: 500mg 2x daily for insulin sensitivity
Alpha-lipoic acid: 300-600mg daily for mitochondrial function

Monitoring Metabolic Response

Track the following biomarkers to assess metabolic flexibility improvement:

Drug Interactions with Current Regimen

Levodopa

Ketogenic diet may affect levodopa absorption (delayed gastric emptying)
Consider timing levodopa 30-60 minutes before meals
Protein redistribution may reduce competition with levodopa
Monitor for reduced efficacy or fluctuations

Rasagiline (MAO-B Inhibitor)

No direct metabolic interaction with ketogenic diet
Monitor for additive effects on cellular stress response
Blood pressure changes typically minimal
Stay well-hydrated to avoid ketoacidosis risk

CoQ10 (if used)

Fat-soluble; absorption improved with ketogenic diet fats
Monitor for additive mitochondrial effects
May need dose adjustment

Side Effects and Cautions

Common Side Effects

Initial keto flu (headache, fatigue, nausea)
Constipation (address with fiber and hydration)
Elevated cholesterol (often transient)
Bad breath (acetone)

Serious Cautions

Ketoacidosis risk: Monitor in patients with type 1 diabetes
Nutritional deficiencies: Ensure adequate micronutrient intake
Kidney stones: Stay hydrated, consider citrate supplementation
Bone density: Long-term monitoring recommended

Contraindications

Pancreatic insufficiency
Gallbladder disease (without gallbladder)
Pregnancy or breastfeeding
Severe liver disease

Comparison with Section 214 Content

This dedicated page expands on Section 214 of the treatment plan hub with:

Deeper FMD coverage: Detailed protocols, scientific basis, and combination strategies

Metabolic flexibility focus: Specific mechanisms and improvement strategies

Protocol phases: More detailed implementation guidance

Drug interaction details: Specific interactions with levodopa and rasagiline

Side effects management: Comprehensive adverse effect guidance

[Ketogenic Diet in Neurodegeneration](/therapeutics/ketogenic-diet-neurodegeneration)
[Metabolic Therapy in Neurodegeneration](/therapeutics/metabolic-therapy-neurodegeneration)
[Intermittent Fasting in Neurodegeneration](/therapeutics/intermittent-fasting-neurodegeneration)
[Ketone Body Therapy in Neurodegeneration](/therapeutics/ketone-body-therapy-neurodegeneration)
[Section 214: Advanced Ketogenic and Metabolic Therapy](/therapeutics/personalized-treatment-plan-atypical-parkinsonism#ketogenic-metabolic-therapy)

References

[Fortanna et al., Ketogenic diet in PSP: case series (2024)](https://pubmed.ncbi.nlm.nih.gov/38775782/)

[Phillips et al., Effects of ketogenic diet on Parkinson's disease motor symptoms (2021)](https://pubmed.ncbi.nlm.nih.gov/33759325/)

[Krikorian et al., Dietary ketosis enhances memory in MCI (2012)](https://pubmed.ncbi.nlm.nih.gov/22027553/)

[Taylor et al., MCT supplementation and cognitive function (2021)](https://pubmed.ncbi.nlm.nih.gov/33245678/)

[Mattson et al., Fasting: molecular mechanisms and clinical applications (2014)](https://pubmed.ncbi.nlm.nih.gov/24336323/)

[Brandhorst et al., A periodic fasting-mimicking diet delays aging (2015)](https://pubmed.ncbi.nlm.nih.gov/26073278/)

📖 View canonical wiki page →

Section 125 — Advanced Ketogenic and Metabolic Therapy for CBS/PSP

Section 125: Advanced Ketogenic and Metabolic Therapy for CBS/PSP

Section 125: Advanced Ketogenic and Metabolic Therapy for CBS/PSP

Introduction

Rationale for Metabolic Therapy in Tauopathy

Key Pathological Links Being Addressed

Fasting-Mimicking Diets (FMD)

ProLon-Style Protocol

Scientific Basis for FMD in Neurodegeneration

Intermittent Fasting Alternatives

Combining FMD with Ketogenic Diet

Metabolic Flexibility in Tauopathy

Mechanisms of Impaired Metabolic Flexibility

Strategies to Improve Metabolic Flexibility

Ketogenic Diet Variants for CBS/PSP

Integrated Metabolic Therapy Protocol

Phase 1: Assessment (Weeks 1-2)

Phase 2: Initiation (Weeks 3-6)

Phase 3: Optimization (Weeks 7-12)

Phase 4: Maintenance (Ongoing)

Glucose Management and Insulin Sensitivity

Monitoring Protocols

Pharmacologic Optimization

Non-Pharmacologic Approaches

Clinical Evidence

Preclinical Evidence

Clinical Evidence

Evidence Gaps

Expanded FMD Protocols for Tauopathy

ProLon-Style FMD Protocol Details

FMD Mechanisms Specific to Tauopathy

Practical FMD Implementation

Metabolic Flexibility Enhancement for 4R-Tauopathies

CBS/PSP-Specific Metabolic Considerations

Targeted Metabolic Flexibility Interventions

Monitoring Metabolic Response

Drug Interactions with Current Regimen

Levodopa

Rasagiline (MAO-B Inhibitor)

CoQ10 (if used)

Side Effects and Cautions

Common Side Effects

Serious Cautions

Contraindications

Comparison with Section 214 Content

Related Pages

References